GlobeImmune GBIM Stock
GlobeImmune Price Chart
GlobeImmune GBIM Financial and Trading Overview
GlobeImmune stock price | 0.0002 USD |
Previous Close | 0.0002 USD |
Open | 0.0002 USD |
Bid | 0 USD x 0 |
Ask | 1.95 USD x 1000 |
Day's Range | 0.0002 - 0.0002 USD |
52 Week Range | 0.0002 - 0.0008 USD |
Volume | 150 USD |
Avg. Volume | 87 USD |
Market Cap | 2.01M USD |
Beta (5Y Monthly) | -178.10422 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
GBIM Valuation Measures
Enterprise Value | -8692568 USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.32402557 |
Price/Book (mrq) | 0.0005347593 |
Enterprise Value/Revenue | -1.399 |
Enterprise Value/EBITDA | 4.478 |
Trading Information
GlobeImmune Stock Price History
Beta (5Y Monthly) | -178.10422 |
52-Week Change | -60.00000000000000000000000000000000% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.0008 USD |
52 Week Low | 0.0002 USD |
50-Day Moving Average | 0.000632 USD |
200-Day Moving Average | 0.000698 USD |
GBIM Share Statistics
Avg. Volume (3 month) | 87 USD |
Avg. Daily Volume (10-Days) | 15 USD |
Shares Outstanding | 5.75M |
Float | 4.37M |
Short Ratio | 0.1 |
% Held by Insiders | 0% |
% Held by Institutions | 0.017% |
Shares Short | 129.39K |
Short % of Float | 3.49% |
Short % of Shares Outstanding | 2.25% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2015 |
Most Recent Quarter (mrq) | March 31, 2016 |
Next Fiscal Year End | December 31, 2016 |
Profitability
Profit Margin | -33.29% |
Operating Margin (ttm) | -33.29% |
Gross Margin | 66.51% |
EBITDA Margin | -31.24% |
Management Effectiveness
Return on Assets (ttm) | -10.25% |
Return on Equity (ttm) | -66.23% |
Income Statement
Revenue (ttm) | 6.21M USD |
Revenue Per Share (ttm) | 1.08 USD |
Quarterly Revenue Growth (yoy) | -20.59% |
Gross Profit (ttm) | 3.81M USD |
EBITDA | -1941195 USD |
Net Income Avi to Common (ttm) | -2068585 USD |
Diluted EPS (ttm) | 0 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 8.69M USD |
Total Cash Per Share (mrq) | 1.51 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.28 |
Book Value Per Share (mrq) | 0.374 |
Cash Flow Statement
Operating Cash Flow (ttm) | -5904894 USD |
Levered Free Cash Flow (ttm) | -1646943 USD |
Profile of GlobeImmune
Country | United States |
State | CO |
City | Louisville |
Address | 1450 Infinite Drive |
ZIP | 80027 |
Phone | 303 625 2700 |
Website | https://www.globeimmune.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 2 |
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.
Q&A For GlobeImmune Stock
What is a current GBIM stock price?
GlobeImmune GBIM stock price today per share is 0.0002 USD.
How to purchase GlobeImmune stock?
You can buy GBIM shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GlobeImmune?
The stock symbol or ticker of GlobeImmune is GBIM.
Which industry does the GlobeImmune company belong to?
The GlobeImmune industry is Biotechnology.
How many shares does GlobeImmune have in circulation?
The max supply of GlobeImmune shares is 10.07B.
What is GlobeImmune Price to Earnings Ratio (PE Ratio)?
GlobeImmune PE Ratio is now.
What was GlobeImmune earnings per share over the trailing 12 months (TTM)?
GlobeImmune EPS is 0 USD over the trailing 12 months.
Which sector does the GlobeImmune company belong to?
The GlobeImmune sector is Healthcare.
GlobeImmune GBIM included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
- {{ link.label }} {{link}}